Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: Results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients

British Journal of Haematology

Volumn 138, Issue 2, 2007, Pages 186-195

  Clavio, Marino ^a   Vignolo, Luana ^a   Albarello, Alessandra ^a   Varaldo, Riccardo ^a   Pierri, Ivana ^a   Catania, Gioacchino ^a   Balocco, Manuela ^a   Michelis, Gianluca ^a   Miglino, Maurizio ^a   Manna, Annunziata ^a   Balleari, Enrico ^a   Carella, A Michele ^a   Sessarego, Mario ^a   Van Lint, Maria Teresa ^a   Bacigalupo, Andrea ^a   Gobbi, Marco ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Acute myeloid leukaemia; Ara C; Fludarabine; Gentuzumab ozogamicin; Idarubicin

Indexed keywords

CD33 ANTIGEN; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADULT; AGED; ARTICLE; ASPERGILLOSIS; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG FEVER; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; KARYOTYPE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG HEMORRHAGE; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIDARABINE;

EID: 34250823073     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06646.x     Document Type: Article

References (41)

1. Alvarado, Y., Tsimberidou, A., Kantarjian, H., Cortes, J., Garcia-Manero, G., Faderl, S., Thomas, D., Estey, E. Giles, F.J. (2003) Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemotherapy Pharmacology, 51, 87 90.
2. Amadori, S., Arcese, W., Isacchi, G., Meloni, G., Petti, M.C., Monarca, B., Testi, A.M. Mandelli, F. (1991) Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. Journal of Clinical Oncology, 9, 1210 1214.
3. Amadori, S., Suciu, S., Willemze, R., Mandelli, F., Selleslag, D., Stauder, R., Ho, A., Denzlinger, C., Leone, G., Fabris, P., Muus, P., Vignetti, M., Hagemeijer, A., Beeldens, F., Anak, O. De Witte, T. (2004) Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA Leukemia groups. Haematologica, 89, 950 956.
4. Apostolidou, E., Cortes, J., Tsimberidou, A., Estey, E., Kantarjian, H. Giles, F.J. (2003) Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leukemia Research, 27, 887 891.
5. Berman, E., Heller, G., Santorsa, J., McKenzie, S., Gee, T., Kempin, S., Gulati, S., Andreeff, M., Kolitz, J. Gabrilove, J. (1991) Results of a randomised trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukaemia. Blood, 77, 1666 1674.
6. Burnett, A.K., Mohite, U. (2006) Treatment of older patients with acute myeloid leukemia-new agents. Seminars in Hematology, 43, 96 106.
7. Burnett, A.K., Kell, W.J., Goldstone, A., Milligan, D., Hunter, A., Prentice, A.G., Russell, N.H., Gibson, B., Wheatley, K. Hills, R.K. (2006) The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 Trial. Blood (ASH Annual Meeting Abstracts), 108, 13.
8. Cassileth, P.A., Lynch, E., Hines, J.D., Oken, M.M., Mazza, J.J., Bennett, J.M., McGlave, P.B., Edelstein, M., Harrington, D.P. O'Connell, M.J. (1992) Varying intensity of post-remission therapy in acute myeloid leukaemia. Blood, 79, 1924 1930.
9. Clavio, M., Carrara, P., Miglino, M., Pierri, I., Canepa, L., Balleari, E., Gatti, A.M., Cerri, R., Celesti, L., Vallebella, E., Sessarego, M., Patrone, F., Ghio, R., Damasio, E. Gobbi, M. (1996) High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica, 81, 513 520.
10. Clavio, M., Gatto, S., Beltrami, G., Quintino, S., Canepa, L., Pierri, I., Galbusera, V., Carrara, P., Miglino, M., Varaldo, R., Ballerini, F., Venturino, C., Cerri, R., Risso, M., Balleari, E., Carella, A.M., Sessarego, M., Ghio, R., Bacigalupo, A. Gobbi, M. (2001) First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukemia. Leukemia and Lymphoma, 40, 305 313.
11. Clavio, M., Gatto, S., Beltrami, G., Quintino, S., Canepa, L., Pierri, I., Galbusera, V., Carrara, P., Miglino, M., Varaldo, R., Ballerini, F., Venturino, C., Cerri, R., Risso, M., Balleari, E., Carella, A.M., Sessarego, M., Ghio, R., Bacigalupo, A. Gobbi, M. (2002) Fludarabine, Ara-C, Idarubicin and G-CSF (FLAG-Ida), high dose Ara-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients. Journal of Experimental Clinical Cancer Research, 21, 481 487.
12. Estey, E. (2000) How I treat older patients with AML. Blood, 96, 1670 1673.
13. Estey, E., Plunkett, W., Gandhi, V., Rios, M.B., Kantarjian, H. Keating, M. (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myeloid leukemia. Leukemia and Lymphoma, 9, 343 350.
14. Estey, E., Thall, P., Andreef, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L.E., Koller, C., Kornblau, S., Pierce, S., Freireich, E., Deisseroth, A. Keating, M. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. Journal of Clinical Oncology, 12, 671 678.
15. Estey, E., Thall, P., Pierce, S., Cortes, J., Beran, M., Kantarjian, H., Keating, M., Andreeff, M. Freireich, E. (1999) Randomized phase II study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood, 93, 2478 2484.
16. Harousseau, J.L., Cahn, J.Y., Pignon, B., Witz, F., Milpied, N., Delain, M., Lioure, B., Lamy, T., Desablens, B., Guilhot, F., Caillot, D., Abgrall, J.F., Francois, S., Briere, J., Guyotat, D., Casassus, P., Audhuy, B., Tellier, Z., Hurteloup, P. Herve, P. (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as post-remission therapy in adult acute myeloid leukemia. Blood, 90, 2978 2986.
17. Kell, W.J., Burnett, A.K., Chopra, R., Yin, J.A., Clark, R.E., Rohatiner, A., Culligan, D., Hunter, A., Prentice, A.G., Milligan, D.W. (2003) A feasibility study of simultaneous administration of GO with intensive chemotherapy in induction and consolidation in younger patients with AML. Blood, 102, 4277 4283.
18. Kolitz, J.E. (2006) Current therapeutic strategies for acute myeloid leukaemia. British Journal of Haematology, 134, 555 572.
19. Larson, R.A., Sievers, E.L., Stadtmauer, E.A., Lowenberg, B., Estey, E.H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J.M., Richie, M., Leopold, L.H., Berger, M.S., Sherman, M.L., Loken, M.R., van Dongen, J.J., Bernstein, I.D., Appelbaum, F.R. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 104, 1442 1452.
20. Leith, C.P., Kopechy, K.J., Godwin, J., McConnel, T., Slovak, M.L., Chen, I.M., Head, D.R., Appelbaum, F.R. Willman, C.L (1997) Acute myeloid leukemia in the elderly: assessment of multidrugs resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct response to standard chemotherapy: a Southwest Oncology Group study. Blood, 89, 3323 3329.
21. Lowenberg, B., Downing, J.R. Burnett, A. (1999) Acute myeloid leukaemia. New England Journal of Medicine, 341, 1051 1062.
22. Malagola, M., Damiani, D., Martinelli, G., Michelutti, A., Cesana, B., Vivo, A.D., Piccaluga, P.P., Ottaviani, E., Candoni, A., Geromin, A., Tiribelli, M., Fanin, R., Testoni, N., Lauria, F., Bocchia, M., Gobbi, M., Pierri, I., Zaccaria, A., Zuffa, E., Mazza, P., Priccolo, G., Gugliotta, L., Bonini, A., Visani, G., Skert, C., Bergonzi, C., Roccaro, A.M., Fili, C., Baccarani, M. Russo, D. (2007) Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. British Journal of Haematology, 136, 87 95.
23. Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R. Frei, E. III. (1994) Intensive post-remission chemotherapy in adults with acute myeloid leukaemia. New England Journal of Medicine, 331, 896 903.
24. McKoy, J.M., Angelotta, C., Bennett, C.L., Tallman, M.S., Wadleigh, M., Evens, A.M., Kuzel, T.M., Trifilio, S.M., Raisch, D.W., Kell, J., Deangelo, D.J. Giles, F.J. (2006) Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leukemia Research, 31, 599 604.
25. Parker, J.E., Pagliuca, A., Mijovic, A., Cullis, J.O., Czepulkowski, B., Rassam, S.M., Samaratunga, I.R., Grace, R., Gover, P.A. Mufti, G.J. (1997) Fludarabine, Cytarabine, G-CSF and idarubicin (Flag-Ida) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia (1997). British Journal of Haematology, 99, 934 944.
26. Piccaluga, P.P., Martinelli, G., Rondoni, M., Malagola, M., Gaitani, S., Isidori, A., Bonini, A., Gugliotta, L., Luppi, M., Morselli, M., Sparaventi, G., Visani, G. Baccarani, M. (2004a) Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leukemia and Lymphoma, 45, 1791 1795.
27. Piccaluga, P.P., Martinelli, G., Rondoni, M., Malagola, M., Gaitani, S., Visani, G. Baccarani, M. (2004b) First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leukemia Research, 28, 987 990.
28. Piccaluga, P.P., Papayannidis, C., Malagola, M., Rondoni, M., Laterza, C., Paolini, S., Russo, D., Candoni, A., Fanin, R., Visani, G., Baccarani, M. Martinelli, G. (2006) Safety and efficacy of the four-drug induction regimen MY-FLAIG-3 (Myelotarg, fludarabine, cytarabine and idarubicin) for elderly acute myeloid leukaemia patients. Results of a phase II pilot study. Haematologica, 91 (Suppl. 3 n101.
29. Pierri, I., Clavio, M., Miglino, M., Cavaliere, M., Pietrasanta, D. Gobbi, M. (1999) GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly. Haematologica, 84, 562 563.
30. Preisler, H., Davis, R.B., Kirshner, J., Dupre, E., Richards, F., III., Hoagland, H.C., Kopel, S., Levy, R.N., Carey, R. Schulman, P. (1987) Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukaemia, a Cancer and Leukemia Group B study. Blood, 69, 1441 1449.
31. Rai, K.R., Holland, J.F., Glidewell, O.J., Weinberg, V., Brunner, K., Obrecht, J.P., Preisler, H.D., Nawabi, I.W., Prager, D., Carey, R.W., Cooper, M.R., Haurani, F., Hutchison, J.L., Silver, R.T., Falkson, G., Wiernik, P., Hoagland, H.C., Bloomfield, C.D., James, G.W., Gottlieb, A., Ramanan, S.V., Blom, J., Nissen, N.I., Bank, A., Ellison, R.R., Kung, F., Henry, P., McIntyre, O.R. Kaan, S.K. (1981) Treatment of acute myelocytic leukaemia: a study by Cancer and Leukemia Group B. Blood, 58, 1203 1212.
32. Rowe, J.M., Andersen, J.W., Mazza, J.J., Bennett, J.M., Paietta, E., Hayes, F.A., Oette, D., Cassileth, P.A., Stadtmauer, E.A. Wiernik, P.H. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Group. Blood, 86, 457 462.
33. Russo, D., Pricolo, G., Michieli, M., Michelutti, A., Raspadori, D., Bertone, A., Marin, L., Pierri, I., Bucalossi, A., Zuffa, E., De Vivo, A., Mazza, P., Gobbi, M., Lauria, F., Zaccaria, A., Baccarani, M. (2001) Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia. Leukemia and Lymphoma, 40, 335 343.
34. Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, S.J., Flowers, D., Smith, F.O., Shannon-Dorcy, K., Berger, M.S. Bernstein, I.D. (1999) Selective ablation of AML using antibody-targeted chemotherapy: a phase I study of an anti-CD 33 calicheamicin immunoconjugate. Blood, 93, 3678 3684.
35. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P.P., Lee, E.J., Moore, J.O., Powell, B.L., Baer, M.R., Bloomfield, C.D. Schiffer, C.A. (2001) Post remission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood, 98, 548 553.
36. Tsimberidou, A., Cortes, J., Thomas, D., Garcia-Manero, G., Verstovsek, S., Faderl, S., Albitar, M., Kantarjian, H., Estey, E. Giles, F.J. (2003a) Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research, 27, 893 897.
37. Tsimberidou, A., Estey, E., Cortes, J., Thomas, D., Faderl, S., Verstovsek, S., Garcia-Manero, G., Keating, M., Albitar, M., O'Brien, S., Kantarjian, H. Giles, F. (2003b) Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer, 97, 1481 1487.
38. Tsimberidou, A.M., Estey, E., Cortes, J.E., Garcia-Manero, G., Faderl, S., Verstovsek, S., Thomas, D.A., Ferrajoli, A., Keating, M.J., O'Brien, S., Kantarjian, H.M. Giles, F.J. (2003c) Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemotherapy Pharmacology, 52, 449 452.
39. Tsimberidou, A.M., Giles, F.J., Estey, E., O'Brien, S., Keating, M.J. Kantarjian, H.M. (2006) The role of gemtuzumab ozogamicin in acute leukaemia therapy. British Journal of Haematology, 132, 398 409.
40. Van der Heiden, P.L., Jedema, I., Willemze, R. Barge, R.M. (2006) Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. European Journal of Haematology, 76, 409 413.
41. Visani, G., Tosi, P., Zinzani, P.L., Manfroi, S., Ottaviani, E., Testoni, N., Clavio, M., Cenacchi, A., Gamberi, B. Carrara, P. (1994) FLAG: an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia, 8, 1842 1846.